- Home
- TKNO vs NTHI Comparison
TKNO vs NTHI Comparison
Compare TKNO & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TKNO | NTHI |
|---|---|---|
| Founded | 1996 | 2008 |
| Country | United States | United States |
| Employees | N/A | 5 |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.1M | 139.1M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | TKNO | NTHI |
|---|---|---|
| Price | $3.71 | $5.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 78.9K | ★ 104.3K |
| Earning Date | 05-06-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.86 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $40,520,000.00 | N/A |
| Revenue This Year | $8.27 | N/A |
| Revenue Next Year | $13.13 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.35 | N/A |
| 52 Week Low | $1.91 | $3.20 |
| 52 Week High | $6.80 | $12.99 |
Technical Indicators
Market Signals| Indicator | TKNO | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 56.80 | 49.35 |
| Support Level | $3.60 | $5.25 |
| Resistance Level | $4.37 | $5.70 |
| Average True Range (ATR) | 0.32 | 0.68 |
| MACD | -0.03 | 0.13 |
| Stochastic Oscillator | 34.46 | 50.35 |
Price Performance
Historical ComparisonAbout TKNO Alpha Teknova Inc.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.